Justin Murray, PhDPrincipal Scientist, Hybrid Modality Engineering at Amgen, Inc.
Justin received his BSc in Chemistry from the Colorado School of Mines. He received his PhD from the University of Wisconsin - Madison under the direction of Prof. Sam Gellman for research on beta-peptide inhibitors of protein-protein interactions. He joined the Peptide Research & Discovery group at Amgen in 2006 and focused his research on disulfide-rich peptide inhibitors of ion channels and developed his interests in high-throughput synthesis, laboratory automation, and conjugation technologies. Now in the Selection & Modality Engineering group, Justin is working to establish oligonucleotide therapeutics as a new modality for Amgen.